Lipocine (LPCN) Asset Utilization Ratio (2018 - 2025)
Lipocine's (LPCN) quarterly Asset Utilization Ratio came in at 0.25 in Q3 2025, down 27.17% YoY from 0.34 in Q3 2024, and up 15.85% on a QoQ basis from 0.22 in Q2 2025.
Lipocine (LPCN) Asset Utilization Ratio (2018 - 2025) Analysis & Trends
Lipocine (LPCN) has 8 years of Asset Utilization Ratio data on file, last reported at 0.25 in Q3 2025.
- Quarterly Asset Utilization Ratio fell 27.17% year-over-year to 0.25 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 0.25 (down 27.17% YoY) and the FY2024 annual result came in at 0.49, up 422.55% from the prior year.
- Asset Utilization Ratio grew to 0.25 in Q3 2025, from 0.22 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.52 in Q4 2024 to a low of 0.0 in Q3 2021.
- A 5-year average of 0.24 and a median of 0.25 in 2025 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 32254.76% — and 2023, when it tumbled 99.54%.
- Tracing LPCN's Asset Utilization Ratio over 5 years: stood at 0.35 in 2021, then plunged by 96.26% to 0.01 in 2022, then surged by 854.42% to 0.12 in 2023, then jumped by 317.99% to 0.52 in 2024, then slumped by 51.86% to 0.25 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.25 (Q3 2025), 0.22 (Q2 2025), and 0.17 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 0.13 |
| 10 | Lipocine | 11.21 Mn | -12.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.25 |
| Jun 30, 2025 | 0.22 |
| Mar 31, 2025 | 0.17 |
| Dec 31, 2024 | 0.52 |
| Sep 30, 2024 | 0.34 |
| Jun 30, 2024 | 0.44 |
| Mar 31, 2024 | 0.43 |
| Dec 31, 2023 | 0.12 |
| Sep 30, 2023 | 0.12 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.02 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | 0.41 |
| Jun 30, 2022 | 0.37 |
| Mar 31, 2022 | 0.32 |
| Dec 31, 2021 | 0.35 |
| Sep 30, 2021 | 0.00 |
| Dec 31, 2020 | 0.01 |
| Sep 30, 2020 | 0.01 |
| Dec 31, 2019 | 0.01 |